Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets.

Jack, Dominic; Nolting, Axel; Galazka, Andrew

Jack, Dominic; Nolting, Axel; Galazka, Andrew.

Jack D; Merck KGaA, Darmstadt, Germany. Electronic address: dominic.jack@merckgroup.com.
Nolting A; Merck KGaA, Darmstadt, Germany.
Galazka A; Merck, Aubonne, Switzerland, a division of Merck KGaA, Darmstadt, Germany.

Mult Scler Relat Disord ; 46: 102469, 2020 11.

Article in English | MEDLINE | ID: covidwho-731875

Subject(s)

COVID-19 Drug Treatment; Cladribine/pharmacology; Immunosuppressive Agents/pharmacology; Multiple Sclerosis/complications; Multiple Sclerosis/virology; SARS-CoV-2/pathogenicity; COVID-19/complications; COVID-19/virology; Humans; Immunosuppressive Agents/adverse effects; Multiple Sclerosis/drug therapy; SARS-CoV-2/drug effects; Tablets/pharmacology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cladribine / SARS-CoV-2 / COVID-19 Drug Treatment / Immunosuppressive Agents / Multiple Sclerosis Topics: Long Covid Limits: Humans Language: English Journal: Mult Scler Relat Disord Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google